PDE Inhibitors for the Treatment of Schizophrenia.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Advances in neurobiology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/978-3-319-58811-7_14PMID 28956340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Possible overlapping time frames of acquisition and consolidation phases in object memory processes: a pharmacological approach

  2016cited by this paper
• Uncovering the function of Disrupted in Schizophrenia 1 through interactions with the cAMP phosphodiesterase PDE4: Contributions of the Houslay lab to molecular psychiatry.

  2016cited by this paper
• Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

  2016cited by this paper
• An emerging role of cGMP in the treatment of schizophrenia: A review.

  2016cited by this paper
• Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress.

  2015cited by this paper
• Inhibition of PDE2A, but not PDE9A, modulates presynaptic short‐term plasticity measured by paired‐pulse facilitation in the CA1 region of the hippocampus

  2015cited by this paper
• Clinical management of negative symptoms of schizophrenia: An update.

  2015cited by this paper
• Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.

  2015cited by this paper
• Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.

  2015cited by this paper
• Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders.

  2015cited by this paper
• Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.

  2015cited by this paper
• Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition

  2015cited by this paper
• Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-321,2,3

  2015cited by this paper
• Structural basis for the design of selective phosphodiesterase 4B inhibitors.

  2014cited by this paper
• Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

  2014cited by this paper
• Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

  2014cited by this paper
• Emerging biology of PDE10A.

  2014cited by this paper
• The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

  2013cited by this paper
• Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801.

  2013cited by this paper
• Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.

  2013cited by this paper
• Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.

  2013cited by this paper
• Role of disrupted in schizophrenia 1 (DISC1) in stress-induced prefrontal cognitive dysfunction

  2013cited by this paper
• Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway.

  2013cited by this paper
• Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.

  2013cited by this paper
• Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.

  2013cited by this paper
• Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.

  2013cited by this paper
• Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update

  2013cited by this paper
• The distribution of phosphodiesterase 2A in the rat brain.

  2012cited by this paper
• Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia

  2012cited by this paper
• The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates.

  2012cited by this paper
• Food and Drug Administration commentary on methodological issues in negative symptom trials.

  2011cited by this paper
• A Phosphodiesterase 2A Isoform Localized to Mitochondria Regulates Respiration*

  2011cited by this paper
• Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.

  2011cited by this paper
• Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex

  2011cited by this paper
• Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes

  2010cited by this paper
• Interplay of Palmitoylation and Phosphorylation in the Trafficking and Localization of Phosphodiesterase 10A: Implications for the Treatment of Schizophrenia

  2010cited by this paper
• Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

  2010cited by this paper
• A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.

  2010cited by this paper
• Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

  2010cited by this paper
• Anxiolytic Effects of Phosphodiesterase-2 Inhibitors Associated with Increased cGMP Signaling

  2009cited by this paper
• A neurodevelopmental model of schizophrenia: Neonatal disconnection of the hippocampus

  2009cited by this paper
• Stress signalling pathways that impair prefrontal cortex structure and function

  2009cited by this paper
• Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

  2009cited by this paper
• Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

  2009cited by this paper
• Schizophrenia, "just the facts" 4. Clinical features and conceptualization.

  2009cited by this paper
• Patented PDE10A inhibitors: novel compounds since 2007

  2009cited by this paper
• Pharmacological Cognitive Enhancement in Schizophrenia

  2009cited by this paper
• Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

  2008cited by this paper
• Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs

  2008cited by this paper
• Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?

  2008cited by this paper
• Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

  2008cited by this paper
• Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)

  2008cited by this paper
• Enhanced long‐term potentiation and impaired learning in phosphodiesterase 4D‐knockout (PDE4D−/−) mice

  2008cited by this paper
• Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum

  2008cited by this paper
• Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

  2008cited by this paper
• The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.

  2008cited by this paper
• Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

  2008cited by this paper
• Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

  2007cited by this paper
• From structure to function

  2007cited by this paper
• Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

  2007cited by this paper
• Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

  2007cited by this paper
• Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

  2007cited by this paper
• Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.

  2007cited by this paper
• Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

  2007cited by this paper
• Behavioral phenotypes of Disc1 missense mutations in mice.

  2007cited by this paper
• Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species

  2006cited by this paper
• The NIMH-MATRICS consensus statement on negative symptoms.

  2006cited by this paper
• Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

  2006cited by this paper
• Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species

  2006cited by this paper
• Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.

  2006cited by this paper
• Under the curve: critical issues for elucidating D1 receptor function in working memory.

  2006cited by this paper
• Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32‐dependent pathways: evidence from PDE1B‐DARPP32 double‐knockout mice

  2006cited by this paper
• Keynote review: phosphodiesterase-4 as a therapeutic target.

  2005cited by this paper
• PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats

  2005cited by this paper
• Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex

  2005cited by this paper
• DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling

  2005cited by this paper
• Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

  2005cited by this paper
• Dopamine, learning and motivation

  2004cited by this paper
• Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

  2004cited by this paper
• Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

  2004cited by this paper
• Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

  2004cited by this paper
• Subcellular Localization of Cyclic Nucleotide Phosphodiesterase Type 10A Variants, and Alteration of the Localization by cAMP-dependent Protein Kinase-dependent Phosphorylation*

  2004cited by this paper
• Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders.

  2004cited by this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cited by this paper
• Dopaminergic Modulation of Visual Attention and Working Memory in the Rodent Prefrontal Cortex

  2004cited by this paper
• Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.

  2003cited by this paper
• Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling*

  2003cited by this paper
• Immunohistochemical localization of PDE10A in the rat brain.

  2003cited by this paper
• Glutamate, Dopamine, and Schizophrenia

  2003cited by this paper
• PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

  2003cited by this paper
• A gene-driven approach to the identification of ENU mutants in the mouse

  2002cited by this paper
• Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning

  2002cited by this paper
• Cyclic nucleotide research — still expanding after half a century

  2002cited by this paper
• Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain

  2002cited by this paper
• PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.

  2001cited by this paper
• Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants.

  2001cited by this paper
• Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

  2000cited by this paper
• Disruption of two novel genes by a translocation co-segregating with schizophrenia.

  2000cited by this paper
• Parallel Information Processing in the Dorsal Striatum: Relation to Hippocampal Function

  1999cited by this paper
• Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits.

  1999cited by this paper

• Individual Brain Structure Deviations and its Gene Expression Signatures in Early-Onset Schizophrenia

  2026cites this paper
• PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges

  2025cites this paper
• Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds

  2025cites this paper
• PDE4B Inhibition: Exploring the Landscape of Chemistry Behind Specific PDE4B Inhibitors, Drug Design, and Discovery

  2025cites this paper
• New pharmacological approaches in the treatment of schizophrenia

  2025cites this paper
• Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology.

  2025cites this paper
• Novel differentially expressed genes and multiple biological pathways for Alzheimer's disease identified in brain tissue from African American donors

  2025cites this paper
• Transcriptome-wide association study of Alzheimer disease reveals many differentially expressed genes and multiple biological pathways in brain tissue from African American donors

  2024cites this paper
• In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia

  2024cites this paper
• GenomeMUSter mouse genetic variation service enables multitrait, multipopulation data integration and analysis

  2024cites this paper
• Phosphodiesterase 2 and Its Isoform a as Therapeutic Targets in the Central Nervous System Disorders.

  2023cites this paper
• GenomeMUSter mouse genetic variation service enables multi-trait, multi-population data integration and analyses

  2023cites this paper
• Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders

  2022cites this paper
• Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains

  2022cites this paper
• Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis.

  2022cites this paper
• Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial

  2022cites this paper
• Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

  2022cites this paper
• Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments

  2021cites this paper
• Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains

  2021influential citation
• Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.

  2021cites this paper
• Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.

  2021cites this paper
• Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats.

  2020cites this paper
• Alpha 7 nicotinic receptor agonist and positive allosteric modulators improved social and molecular deficits of MK-801 model of schizophrenia in rats.

  2020cites this paper
• Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.

  2020cites this paper
• Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid.

  2020cites this paper
• Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development.

  2020cites this paper
• Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.

  2020cites this paper
• Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies.

  2019cites this paper
• Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.

  2019cites this paper
• Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.

  2018cites this paper
• Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway

  2018cites this paper
• Multi-Target Approach for Drug Discovery against Schizophrenia

  2018cites this paper
• Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder

  2018cites this paper